SUCNR1 and renal cell carcinoma: Effectiveness of these novel drugs may likely be extended to unresectable or metastatic SDH-deficient renal cell carcinomas, gastrointestinal stroma tumors, thyroid, and pancreatic neuroendocrine tumors, or other conditions exhibiting disturbed SUCNR1-signaling due to hypoxia or hyperglycemia.